Sources and References: Hikma Pharmaceuticals PLC
UK-based health technology company Rem3dy Health has secured a strategic investment from Hikma Ventures, the corporate venture capital arm of Hikma Pharmaceuticals, to support its expansion across the Middle East and North Africa (MENA). The investment builds on an exclusive commercial partnership through which Hikma will introduce Rem3dy Health’s Nourished personalised nutritional supplements across seven regional markets.
The companies plan to launch the products in the UAE, Saudi Arabia and Jordan in the first quarter of 2027, followed by Qatar, Kuwait, Oman and Bahrain. The financial terms of the investment have not been disclosed.
Founded in 2019 by Melissa Snover, Rem3dy Health combines 3D printing, material science and artificial intelligence to develop personalised nutritional supplements. Its patented technology can combine multiple active ingredients into a single seven-layer gummy. The company’s intellectual property portfolio includes 29 patents.
Click here to join our WhatsApp channel here
The Nourished products planned for the regional markets will initially focus on cognitive wellbeing, gut health, hair and nail health, and sleep. Manufacturing will take place in the UK, with Hikma supporting regional commercialisation through its established presence and expertise.
“At Hikma, we are constantly looking for innovative companies that are shaping the future of healthcare. Rem3dy Health combines differentiated technology, strong consumer engagement, and a compelling vision for personalised wellness. This investment reflects Hikma Ventures’ strategy of backing high-growth healthcare businesses that not only have significant commercial potential but can also create strategic value across Hikma’s businesses and markets,” said Lana Ghanem, Vice President Corporate Development at Hikma Pharmaceuticals and Managing Director of Hikma Ventures.
The investment marks Hikma Ventures’ first move into the health and wellness innovation sector. It also follows Rem3dy Health’s reported 61% revenue growth in 2025, taking annual revenue to £10.2 million.
The partnership brings together Rem3dy Health’s personalised nutrition technology and manufacturing capabilities with Hikma’s regional network, creating a pathway for the UK-developed products to reach consumers across the Middle East.
Also read: Pfizer Secures $1.5B Deal for Obesity Drug
